Gerdtsson Axel, Poon Jessica B, Thorek Daniel L, Mucci Lorelei A, Evans Michael J, Scardino Peter, Abrahamsson Per-Anders, Nilsson Peter, Manjer Jonas, Bjartell Anders, Malm Johan, Vickers Andrew, Freedland Stephen J, Lilja Hans, Ulmert David
Department of Clinical Sciences (Urology), Lund University, Skåne University Hospital, Malmö, Sweden; Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.
Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Eur Urol. 2015 Dec;68(6):1076-82. doi: 10.1016/j.eururo.2015.03.017. Epub 2015 Mar 18.
Previous studies of prostate cancer (PCa) risk and anthropometrics (ie, body measurements) were based on single measurements or obtained over limited time spans.
To study the association between anthropometrics measured at multiple time points in life and their relation to later diagnosis, metastasis, or death from PCa.
DESIGN, SETTING, AND PARTICIPANTS: This case-control study includes 27 167 Swedish men enrolled in two population-based projects from 1974 to 1996. PCa diagnosis up to December 31, 2006, disease information, gestation time, and anthropometrics at birth, military conscript testing, and adulthood were collected. A total of 1355 PCa cases were matched with 5271 controls.
Univariate conditional logistic regression was used to determine whether clinical diagnosis, metastasis, or PCa death was associated with low birth weight (weight <2500 g); with small size for gestational age; or with weight, length, or body mass index (BMI) at birth, adolescence (aged 16-22 yr), or early middle age (aged 44-50 yr).
Apart from weight at adolescence, which was associated with an increased risk of PCa diagnosis (odds ratio [OR] per 5 kg: 1.05; 95% confidence interval [CI], 1.01-1.09; p=0.026), preadulthood measurements were not associated with any PCa end point. Adulthood parameters were not associated with diagnosis. In contrast, weight and BMI at early middle age were significantly associated with metastasis (OR per 5 kg: 1.13; 95% CI, 1.06-1.20; p<0.0001, and OR: 1.09; 95% CI, 1.05-1.14; p<0.0001) and death (OR per 5 kg: 1.11 (95% CI, 1.03-1.19; p=0.005, and OR: 1.08; 95% CI, 1.03-1.13; p=0.003), respectively. It remains unclear whether these results apply to men of nonwhite origin, to populations with active PCa screening programs, or to countries without socialized health care.
The analyses of these large data sets demonstrate that significant effects of body characteristics (with links to metabolic syndrome) measured at early middle age are associated with PCa disease severity, metastatic progression, and outcome. Conversely, measurements at birth and adolescence are not associated with PCa prevalence or outcome.
Increased weight and body mass index in adults is associated with a higher risk of prostate cancer metastasis and death.
先前关于前列腺癌(PCa)风险与人体测量学(即身体测量)的研究基于单次测量或在有限时间段内获得的数据。
研究在生命中多个时间点测量的人体测量学指标与随后前列腺癌诊断、转移或死亡之间的关联。
设计、地点和参与者:这项病例对照研究纳入了1974年至1996年参与两项基于人群项目的27167名瑞典男性。收集了截至2006年12月31日的前列腺癌诊断信息、疾病信息、妊娠期以及出生时、征兵体检时和成年期的人体测量数据。总共1355例前列腺癌病例与5271名对照进行匹配。
采用单变量条件逻辑回归来确定临床诊断、转移或前列腺癌死亡是否与低出生体重(体重<2500 g)、小于胎龄儿或出生时、青春期(16 - 22岁)或中年早期(44 - 50岁)的体重、身长或体重指数(BMI)相关。
除青春期体重与前列腺癌诊断风险增加相关外(每增加5 kg的比值比[OR]:1.05;95%置信区间[CI],1.01 - 1.09;p = 0.026),成年前测量指标与任何前列腺癌终点均无关联。成年期参数与诊断无关。相反,中年早期的体重和BMI与转移(每增加5 kg的OR:1.13;95% CI,1.06 - 1.20;p < 0.0001,以及OR:1.09;95% CI,1.05 - 1.14;p < 0.0001)和死亡(每增加5 kg的OR:1.11(95% CI,1.03 - 1.19;p = 0.005,以及OR:1.08;95% CI,1.03 - 1.13;p = 0.003))分别显著相关。这些结果是否适用于非白人男性、有活跃前列腺癌筛查项目的人群或没有社会化医疗保健的国家仍不清楚。
对这些大型数据集的分析表明,中年早期测量的身体特征(与代谢综合征相关)的显著影响与前列腺癌疾病严重程度、转移进展和结局相关。相反,出生时和青春期的测量与前列腺癌患病率或结局无关。
成年人体重和体重指数增加与前列腺癌转移和死亡风险较高相关。